A leading provider of
innovative DNA Screening solutions
IGH Breakapart LPH 014
In ALL, IGH is most notably involved in rearrangements involving the cMYC oncogene as a result of the t(8;14) translocation. However, less common rearrangements of the IGH gene are most often seen in T-ALL and also in B-ALL. There are a number of stereotypical translocations involved in each of the two diseases and more are being described regularly.
In CLL, around 20% of cytogenetically abnormal CLL patients have a detectable 14q+ marker chromosome. The markers are derived from reciprocal translocations involving a number of fusion partners from different chromosomes that fuse with the IGH gene at 14q32. Involvement of chromosomes 1, 2, 5, 6, 7, 8, 9, 11, 12, 13, 14, 17, 18, 19 and 22 have been described and the two most common translocations are IGH/BCL2 involving the t(14;18) translocation and IGH/CCND1 involving the t(11;14) translocation.
IGH Breakapart
Cat. No. LPH 014-S (5 tests)
Cat. No. LPH 014 (10 tests)
IGH Breakapart
(IGH Translocation patient)
- ALL
- CLL
- MM
- L
This webpage could contain information on product details or information not valid in your country or region. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration or usage in the country of your origin. If you are a resident of a country other than those to which this site is directed, contact your local Cytocell distributor to obtain the appropriate product information for your country of residence.
Developed &produced in the UK